Skip to main content

AstraZeneca will acquire Alexion Pharmaceuticals in $39 billion push into rare diseases and immunology

AstraZeneca has agreed to buy U.S. Alexion Pharmaceuticals for $39 billion, betting on rare diseases and immunology as the British drug company emerges as one of the leading developers of a COVID-19 vaccine.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.